United Therapeutics
UTHR
505 hedge funds and large institutions have $10.1B invested in United Therapeutics in 2023 Q1 according to their latest regulatory filings, with 84 funds opening new positions, 184 increasing their positions, 165 reducing their positions, and 87 closing their positions.
12% more repeat investments, than reductions
Existing positions increased: 184 | Existing positions reduced: 165
1.32% more ownership
Funds ownership: 97.33% → 98.65% (+1.3%)
3% less first-time investments, than exits
New positions opened: 84 | Existing positions closed: 87
6% less call options, than puts
Call options by funds: $40.2M | Put options by funds: $42.6M
1% less funds holding
Funds holding: 511 → 505 (-6)
18% less capital invested
Capital invested by funds: $12.3B → $10.1B (-$2.19B)
26% less funds holding in top 10
Funds holding in top 10: 23 → 17 (-6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$299M |
| 2 |
Envestnet Asset Management
Chicago,
Illinois
|
+$118M |
| 3 |
State Street
Boston,
Massachusetts
|
+$60.6M |
| 4 |
BlackRock
New York
|
+$59.6M |
| 5 |
Janus Henderson Group
London,
|
+$51.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$218M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$66.8M |
| 3 |
Millennium Management
New York
|
-$61.7M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$52.6M |
| 5 |
FAM
Fred Alger Management
New York
|
-$45.2M |
UTHR Hedge Fund Activity: Q1 2023 in Review
505 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q1 2023, worth a combined $10.1B — down 18% from $12.3B a quarter earlier.
Sellers outnumbered buyers: 87 funds closed out of UTHR and 84 opened new positions — a net loss of 3 holders — while 165 trimmed existing stakes and 184 added.
The largest buyer was Wellington Management Group, adding an estimated $299M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $218M sold.
- 505 institutional investors held United Therapeutics (UTHR) as of Q1 2023, down from 511 in Q4 2022.
- Funds reported $10.1B of United Therapeutics stock for Q1 2023, down 18% quarter-over-quarter.
- 84 funds opened new United Therapeutics positions in Q1 2023 and 87 closed out, a net change of -3 holders.
- The largest United Therapeutics buyer in Q1 2023 was Wellington Management Group, an estimated $299M added.
- The largest United Therapeutics seller in Q1 2023 was Avidity Partners Management, an estimated $218M sold.
Based on aggregated 13F filings for Q1 2023.